ArticleBMC microbiology2026
Dysregulated myeloid-T cell immunity in refractory Mycoplasma pneumoniae pneumonia: high inflammation meets T cell suppression.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough the clinical burden associated with refractory Mycoplasma pneumoniae pneumonia (RMPP) has been continuously increasing in recent years, the immunological mechanisms of RMPP remain poorly understood.
methodsA total of 27 RMPP patients, 24 general Mycoplasma pneumoniae pneumonia (GMPP) patients, and 24 bronchial foreign body patients were enrolled in this study. Protein array technology was used to assess the cytokine profiles in bronchoalveolar lavage fluid (BALF) samples from the patients. Functional interactions among differentially expressed cytokines (DECs) were investigated using protein-protein interaction (PPI) network and pathway enrichment analyses. The impact of DECs on the clinical prognosis and laboratory indicators of the patients was further analyzed in conjunction with clinical data.
resultsSeven DECs were identified: T cell-associated (IL-12p70, IFN-γ, IL-7, IL-4) and myeloid-associated (IL-8, MCP-1, MIP-1β). Compared with GMPP, RMPP BALF showed significantly decreased T cell cytokines and elevated myeloid cytokines. Pathway enrichment analysis revealed these DECs were significantly enriched in the JAK-STAT signaling pathway. ROC analysis suggested that IL-12p70 and IL-4 had the highest discriminative ability among the DECs, but these results are preliminary due to the limited sample size and need external validation. Furthermore, all seven DECs showed correlations with patients' clinical indicators and prognostic parameters.
conclusionsRMPP exhibits a dual immune dysregulation: myeloid hyperinflammation and T cell suppression, with the dysregulated cytokine network converging on JAK-STAT signaling. This provides novel mechanistic insights and identifies potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.